Clinical Trials

A Phase 3 Randomized, Double-blind, Placebo-controlled, Study of Bleximenib, Venetoclax, and Azacitidine for the Treatment of Participants with Newly Diagnosed Acute Myeloid Leukemia Harboring KMT2ARearrangements or NPM1Mutations Who Are Ineligible for Intensive Chemotherapy

EudraCT / EU CT No
2024-520154-38-00
Protocol No
75276617AML3001

Trial information

Medical condition
Untreated AML
Trial phase
Phase 3
Sponsor
Janssen Research & Development, LLC
Start date
25/06/2025
End date
Recruiting
Main objective
CR and OS

Locations and Contact points